Phaseline

Targets › SV2A

SV2A (Synaptic vesicle glycoprotein 2A): drug programs, companies and trials

15 programs from 15 companies in 18 trials: 7 Phase 3, 6 Phase 2, 3 Phase 1, 2 Phase 4; Neurology, Oncology, Psychiatry; next expected readout Dec 2026.

Plays a role in the control of regulated secretion in neural and endocrine cells, enhancing selectively low-frequency neurotransmission. Positively regulates vesicle fusion by maintaining the readily releasable pool of secretory vesicles (By similarity)..; FUNCTION: (Microbial infection) Receptor for the C.botulinum neurotoxin type A2 (BoNT/A, botA); glycosylation is not essential but enhances the interaction. (UniProt, Q7L0J3)

Open in Phaseline: the race on SV2A, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
All India Institute of Medical Sciences, JodhpurLevetiracetam
Synaptic vesicle glycoprotein 2A modulator; Voltage-gated N-type calcium channel alpha-1B subunit blocker
SV2A, Ion channelsPhase 4SeizuresMar 2027
Leiden University Medical CenterLevetiracetam
Synaptic vesicle glycoprotein 2A modulator; Voltage-gated N-type calcium channel alpha-1B subunit blocker
SV2A, Ion channelsPhase 4GliomaJan 2028
Beijing Tiantan HospitalLevetiracetam
Synaptic vesicle glycoprotein 2A modulator; Voltage-gated N-type calcium channel alpha-1B subunit blocker
SV2A, Ion channelsPhase 3Postoperative Seizures After Brain Tumor SurgeryJan 2027
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauLevetiracetam
Synaptic vesicle glycoprotein 2A modulator; Voltage-gated N-type calcium channel alpha-1B subunit blocker
SV2A, Ion channelsPhase 3Down SyndromeDec 2027
Waad AlkathiriLevetiracetam
Synaptic vesicle glycoprotein 2A modulator; Voltage-gated N-type calcium channel alpha-1B subunit blocker
SV2A, Ion channelsPhase 3EpilepsyDec 2028
Shanghai East HospitalLevetiracetam
Synaptic vesicle glycoprotein 2A modulator; Voltage-gated N-type calcium channel alpha-1B subunit blocker
SV2A, Ion channelsPhase 3Suspected StrokeDec 2028
UCB Biopharma SRLBrivaracetam
Synaptic vesicle glycoprotein 2A modulator
SV2APhase 3Childhood Absence Epilepsy; EpilepsyNov 2029
Tata Memorial CentreLevetiracetam
Synaptic vesicle glycoprotein 2A modulator; Voltage-gated N-type calcium channel alpha-1B subunit blocker
SV2A, Ion channelsPhase 3SeizuresJun 2031
Johns Hopkins UniversityLevetiracetam (AGB101)
Synaptic vesicle glycoprotein 2A modulator; Voltage-gated N-type calcium channel alpha-1B subunit blocker
SV2A, Ion channelsPhase 2Parkinson Disease Psychosis; Hippocampal OveractivityDec 2026
University of California, San DiegoLevetiracetam
Synaptic vesicle glycoprotein 2A modulator; Voltage-gated N-type calcium channel alpha-1B subunit blocker
SV2A, Ion channelsPhase 2Neonatal SeizureJul 2027
Sunnybrook Health Sciences CentreLevetiracetam
Synaptic vesicle glycoprotein 2A modulator; Voltage-gated N-type calcium channel alpha-1B subunit blocker
SV2A, Ion channelsPhase 2Hippocampal HyperactivationDec 2027
Ayal A. Aizer, MDLevetiracetam
Synaptic vesicle glycoprotein 2A modulator; Voltage-gated N-type calcium channel alpha-1B subunit blocker
SV2A, Ion channelsPhase 2SeizuresFeb 2029
Sohag UniversityLevetiracetam
Synaptic vesicle glycoprotein 2A modulator; Voltage-gated N-type calcium channel alpha-1B subunit blocker
SV2A, Ion channelsPhase 2Generalized Convulsive Status Epilepticus–
Yale University[11C]UCB-J
SV2A radiotracer for imaging synaptic density
SV2APhase 1Cannabis Use; HIV Associated Neurocognitive DisorderDec 2026
Davidzon, Guido, M.D.[11C]UCB-J
SV2A positron emission tomography (PET) tracer
SV2APhase 1Schizophrenia–

Conditions

Seizures (3) Epilepsy (2) Schizophrenia (1) Postoperative Seizures After Brain Tumor Surgery (1) Neonatal Seizure (1) Parkinson Disease Psychosis (1) Hippocampal Overactivity (1) Generalized Convulsive Status Epilepticus (1) Cannabis Use (1) HIV Associated Neurocognitive Disorder (1) Childhood Absence Epilepsy (1) Hippocampal Hyperactivation (1)

Modalities

small molecule (15)

Companies

Davidzon, Guido, M.D. (1) Beijing Tiantan Hospital (1) University of California, San Diego (1) Johns Hopkins University (1) Waad Alkathiri (1) Sohag University (1) Ayal A. Aizer, MD (1) Yale University (1) UCB Biopharma SRL (1) Tata Memorial Centre (1) Sunnybrook Health Sciences Centre (1) Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau (1) All India Institute of Medical Sciences, Jodhpur (1) Leiden University Medical Center (1) Shanghai East Hospital (1)

Related targets

Ion channels (12)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.